Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study-MedSci.cn

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study

Knop, S; Stuebig, T; Kull, M; Greil, R; Steiner, N; Bassermann, F; Nogai, A; von Lilienfeld-Toal, M; Janjetovic, S; Trautmann-Grill, K; Bittrich, M; Engelhardt, MM; Hoferer, A; Theurich, S; Binder, M; Zojer, N; Duerk, HA; Brueggemann, M; Held, S; Einsele, H

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study

科室

工具

服务